Correction to: Reduction in kidney function decline and risk of severe clinical events in agalsidase beta-treated Fabry disease patients: a matched analysis from the Fabry Registry.
修正：在接受 agalsidase beta 治療的 Fabry 病患者中，腎功能下降及嚴重臨床事件風險的減少：來自 Fabry 註冊的匹配分析。
Clin Kidney J 2024-10-18
Corrigendum to "WCN24-813 MANAGEMENT OF ACUTE FLUID OVERLOAD IN HEART FAILURE PATIENTS WITH CKD USING HOME DELIVERED SUBCUTANEOUS FUROSEMIDE" [<i>Kidney International Reports</i> Volume 9, Issue 4, Supplement, April 2024, Page S251-S252].
對於「WCN24-813 心衰竭合併慢性腎病患者急性液體過載的管理：使用居家配送的皮下注射 Furosemide」的更正 [<i>Kidney International Reports</i> 第9卷，第4期，補充，2024年4月，頁S251-S252]。
Kidney Int Rep 2024-09-18
看起來你提到的是一篇有特定 DOI 的文章的更正。如果你需要幫助理解這個更正、總結文章內容，或是其他相關的問題，請提供更多細節！
PubMedDOI
Correction to: Mortality associated with the COVID-19 pandemic in the Swiss dialysis population beyond SARS-CoV-2 infection.
修正：瑞士透析人群中與 COVID-19 大流行相關的死亡率超越 SARS-CoV-2 感染。
Clin Kidney J 2025-02-17
Corrigendum to "Renal Disease in Metabolic Syndrome: the Hidden Role of Intrarenal Ischemia" [<i>Kidney International Reports</i> Volume 9, Issue 5, May 2024, Pages 1419-1428].
對於「Renal Disease in Metabolic Syndrome: the Hidden Role of Intrarenal Ischemia」的更正 [<i>Kidney International Reports</i> 第9卷，第5期，2024年5月，頁1419-1428]。
Kidney Int Rep 2025-02-24
Corrigendum to "Combination of Cardiovascular, Kidney, and Metabolic Diseases in a Syndrome Named Cardiovascular-Kidney-Metabolic, With New Risk Prediction Equations" [<i>Kidney International Reports</i> Volume 9, Issue 9, September 2024, Pages 2608-2618].
對於「Combination of Cardiovascular, Kidney, and Metabolic Diseases in a Syndrome Named Cardiovascular-Kidney-Metabolic, With New Risk Prediction Equations」的更正 [<i>Kidney International Reports</i> 第9卷，第9期，2024年9月，頁2608-2618]。
Kidney Int Rep 2025-04-14
Corrigendum to "WCN25-3808 NAFLD IN ESRD - PREVALENCE OF NAFLD in ESRD PATIENTS AND EVALUATION OF THERAPEUTIC EFFICACY OF TOCOTRIENOL IN TREATMENT OF NAFLD" [<i>Kidney International Reports</i> Volume 10, Issue 2, Supplement, February 2025, Pages S339-S340].
更正啟事：「WCN25-3808 末期腎臟病（ESRD）中的非酒精性脂肪肝病（NAFLD）—ESRD 患者中 NAFLD 的盛行率及 tocotrienol 治療 NAFLD 療效之評估」[《Kidney International Reports》2025年2月，第10卷，第2期，增刊，S339-S340頁]
Kidney Int Rep 2025-04-30
Correction to: The ERA Registry Annual Report 2022: Epidemiology of Kidney Replacement Therapy in Europe, with a focus on sex comparison.
更正：ERA Registry 2022 年度報告：歐洲腎臟替代治療流行病學，聚焦性別比較
Clin Kidney J 2025-05-07
Correction to: The benefit of reduced serum phosphate levels depends on patient characteristics: a nationwide cohort study.
更正：降低血清磷酸鹽濃度的益處取決於病人特徵：全國性世代研究
Clin Kidney J 2025-06-11
Correction to: Recognition of intraglomerular histological features with deep learning in protocol transplant biopsies and their association with kidney function and prognosis.
更正：利用深度學習辨識腎臟移植活檢中腎小球內組織學特徵及其與腎功能和預後的關聯
Clin Kidney J 2025-06-26
Correction to: The management of chronic kidney disease in primary care in Denmark: patient characteristics, treatment, follow-up, progression and referral.
更正：丹麥基層醫療中慢性腎臟病的管理：病人特徵、治療、追蹤、進展與轉診
Clin Kidney J 2025-07-02
Erratum to "Advancing Understanding of Mitochondrial Function in Diabetic Kidney Disease" [<i>Kidney International Reports</i> Volume 10, Issue 2, February 2025, Pages 285-286].
「更正啟事：『推進對糖尿病腎病變中線粒體功能的理解』［Kidney International Reports 第10卷第2期，2025年2月，頁285-286］」
Kidney Int Rep 2025-07-09
這則通知是針對 DOI 10.1016/j.ekir.2024.12.001 的文章做更正，主要是修正原文的錯誤或補充最新資訊。詳細內容請直接參考該篇文章的更正說明。
PubMedDOI